The rising incidences of kidney failure and kidney-related disease in people above 30 years of age are driving the market's growth.
Newark, May 24, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global dialyzer market is expected to grow from 2700 million in 2021 to USD 5007.5 million by 2030, at a CAGR of 7.1% during the forecast period 2022-2030.
Request a Sample Copy of the Research Report: https://www.thebrainyinsights.com/enquiry/sample-request/12754
As per a study, there has been a rise in end-stage renal disease (ESRD) patients in developed and developing countries. There is also an increase in the number of patients suffering from kidney failure due to hypertension and diabetes mellitus. The current projections indicate that people suffering from end-stage renal disease (ESRD) will reach almost 2.5 billion by 2030. These people require hemodialysis for treatment. According to the Centre for Disease Control, the prevalence of chronic kidney disease in adults aged 30 years or older is rapidly increasing. Covid-19 was declared a global pandemic by the World Health Organization (WHO) in January 2020. The lockdown imposed affected the market for dialyzer as several production units were put on hold. The market was also affected due to the lack of labor and disruptions in the supply of raw materials. As per the National Kidney Foundation, in countries like Brazil, Germany, the U.S., Japan, and Italy, almost 2.3 million people receive kidney failure treatment.
To enhance their market position in the global dialyzer market, the key players are now focusing on adopting the strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.
● In January 2019, A Singapore-based company, AWAK Technologies, developed a portable and wearable peritoneal dialysis device approved by the FDA. This device was specially designed for patients with end-stage renal disease (ESRD) and was created by studying the safety trial results from humans in October 2018 at Singapore General Hospital.
For more information about this report visit: https://www.thebrainyinsights.com/report/dialyzer-market-12754
The rising geriatric population is prone to chronic diseases like hypertension, diabetes, cancer, and other chronic diseases that lead to kidney failure and end-stage renal disease (ESRD). This is driving the market growth for dialyzer. However, the complications related to hemodialyses, such as excessive fluid in the blood and severe anemia, hamper the market's growth. The technological advancements in the healthcare sector and lucrative government reimbursement policies are expected to be an opportunity for market growth during the forecast period. The need for frequent dialysis sessions s is a high-cost procedure that is a challenge for the market's growth. Dialysis treatment creates a substantial financial burden on the majority of developing countries.
● In 2021, the high flux dialyzer segment dominated the market with the largest market share of 72% and market revenue of 1944 million. The product type segment is divided into low-flux dialyzer and high-flux dialyzer. In 2021, the high flux dialyzer segment dominated the market with the largest market share of 72% and market revenue of 1944 million. High flux dialyzers are used for removing bigger toxin molecules from the blood during hemodialysis, which is expected to boost the market growth for dialyzers. ● In 2021, the in-center segment accounted for the largest share of the market, with 63% and market revenue of 1701 million.
The end-user segment is divided into In-centre and home dialysis. In 2021, the in-center segment accounted for the largest share of the market, with 63% and market revenue of 1701 million. The in-center dialysis facilities have the presence of trained medical personnel who can provide better services along with the management services and high-quality care services provided to the patient. The in-center also uses high-grade equipment, which helps increase the accuracy of the dialysis. This drives the market growth in the segment.
Purchase this report (Price 4700 USD for a single-user license) at: https://www.thebrainyinsights.com/buy-now/12754/single
Regional Segment Analysis of the Dialyzer Market
● North America (U.S., Canada, Mexico) ● Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) ● Asia-Pacific (China, Japan, India, Rest of APAC) ● South America (Brazil and Rest of South America) ● The Middle East and Africa (UAE, South Africa, Rest of MEA)
Among all regions, North America emerged as the largest market for the global dialyzer market, with a market share of around 43% and 1161 million of the market revenue in 2021. The increased initiatives by the government to aid in providing dialysis facilities to all kind of patients also helps manufacturers with investment and funding so that they can provide high-quality dialysis. The prevalence of end-stage renal disease coupled with the rising demand for hemodialysis is also expected to propel the market growth in the region.
Key players operating in the Global Dialyzer Market are:
● B. Braun Melsungen AG ● China Chengdu Wesley Biotech Co. ● Baxter International Inc. ● Farmasol ● Allmed Medical Care Holdings Limited ● Medica Group ● Medivators, Inc. ● Kawasumi Laboratories Inc. ● Dialifegroup
This study forecasts revenue at global, regional, and country levels from 2022 to 2030. Brainy Insights has segmented the global dialyzer market based on the below-mentioned segments:
Global Dialyzer Market by Product Type:
Global Dialyzer Market by End-User:
Have Any Query? Ask Our Experts: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/12754
The global dialyzer market is analyzed based on value (USD Million). All the segments have been analyzed worldwide, regional, and country basis. The study includes the analysis of more than 30 countries for each part. The report analyzes driving factors, opportunities, restraints, and challenges for gaining critical insight into the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution, and marketing channels analysis.
The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.
Avinash D Head of Business Development Phone: +1-315-215-1633 Email: sales@thebrainyinsights.com Web: http://www.thebrainyinsights.com
Neither the bear market nor the stock split will have a lasting effect on this company's long-term potential.
Bridgewater’s co–chief investment officer said the U.S. economy could slow down further.
For the second time in three years, Tesla will split its stock, lowering its price and increasing the number of shares outstanding.
Los Angeles Capital CIO Hal Reynolds and Truist Chief Market Strategist Keith Lerner join Yahoo Finance Live to examine market sell-offs amid rising inflation and CPI data, defensive portfolio investing, the Fed's interest rate hike cycles, and spiking oil and gas prices.
(Bloomberg) -- Former Treasury Secretary Lawrence Summers said the Federal Reserve has failed to account for its mistakes and to realize the damage to its credibility after the latest inflation data dashed hopes that a peak had been reached.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenEating Two Portions of Fish Per Week Linked to Deadly Skin CancerFive Key Moments From the Jan. 6 Capitol Riot He
The U.S. hasn't yet entered a recession -- which is officially defined as two consecutive quarters of negative GDP growth -- but runaway inflation, stagnant wages, food shortages, rising interest rates, and geopolitical turmoil could all break this fragile economy's back in the near future. If that happens, growth stocks will fall further as value stocks become even more attractive. Altria is the top tobacco company in America.
Since taking the reins as CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, Warren Buffett has put on a moneymaking clinic for Wall Street. While there are no shortage of reasons for the Oracle of Omaha's sustained success, his love of dividend stocks could be the most important component. Dividend stocks are almost always profitable and time-tested.
(Bloomberg) -- When the nineties ended, an overvalued stock market took three long years to rid itself of its accumulated excess in what is now known as the dot-com crash.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenEating Two Portions of Fish Per Week Linked to Deadly Skin CancerFive Key Moments From the Jan. 6 Capitol Riot HearingYields Spike to 2008 High, Stocks Sink on Fed Bets: Markets WrapT
Yahoo Finance Live’s Brian Sozzi, Brad Smith, and Julie Hyman discuss quarterly earnings for DocuSign.
Shares of several major bank stocks took a hit today after new data showed that inflation is still surging and may not have peaked yet. The Dow Jones Industrial Average had lost more than 650 points as of this writing while the Nasdaq Composite was down close to 3%. Shares of Citigroup (NYSE: C) traded 4.3% lower as of 2:25 p.m. ET today, shares of JPMorgan Chase (NYSE: JPM) were 4.2% lower, and shares of Goldman Sachs (NYSE: GS) were down 4.8%.
In this article, we discuss 10 beaten-down Asian stocks to buy today. If you want to see more stocks in this selection, click 5 Beaten-Down Asian Stocks to Buy Today. While the US dollar remains strong, Asian markets on June 10 stumbled on the back of higher rates guidance from the European Central Bank and […]
NEW YORK (Reuters) -Oil prices fell on Friday, after U.S. consumer prices rose more than expected and China imposed new COVID-19 lockdown measures. Brent crude fell $1.06 to settle at $122.01 a barrel. Both benchmarks still posted weekly gains, 1.9% for Brent and 1.5% for WTI.
“Ball of confusion, that's what the world is today,” sang the Temptations on their 1970 classic, a sentiment which can readily apply to the stock market’s present state. It’s hard to get a grip on the market’s choppy action in 2022 and investors could use a clear signal to follow when considering a new investment. One way to get a head start is by tracking the moves of the insiders. These are the corporate officers with in-depth knowledge of the companies they helm. To keep the playing field lev
ChargePoint, Autoliv, and QuantumScape look like excellent long-term bets, despite the near-term headwinds they face.
Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.
Friday’s consumer-price index report for May — which showed the annual headline U.S. inflation rate climbing to 8.6% in May, with few signs of having peaked — is boosting the chances of a jumbo-sized rate increase by monetary-policy makers as soon as next week, and eliciting dire warnings that central bankers have completely lost control of prices. Fed funds futures traders now see a 21% chance of a 75-basis-point hike in June, up from just 3.6% on Thursday, according to the CME FedWatch Tool. Beneath the issue of where the Fed goes from here is a much more fundamental and serious problem: Some observers fear the U.S. central bank has already effectively lost control of inflation.
Markets are volatile. Use these dividend stocks for peace of mind.
Be greedy (but selective) when others are fearful.
Yahoo Finance Live's Seana Smith reports breaking news that EV manufacturer Tesla has filed for a 3-for-1 stock split.
Inflation remains white-hot. These stocks can help stop the pain.